ADC and T2 response to radiotherapy in a human tumour xenograft model

Medicilon offers fully integrated pharmaceutical services for the global scientific community. We focus on providing an exceptional client-centered experience and advancing the drug discovery process.

Email: Marketing@medicilon.com.cn Website: www.medicilon.com

Address: 585 Chuanda Road, Shanghai 201299, China

Tel: +86 (21) 5859-1500 Fax: +86 (21) 5859-6369

A 9.4 T magnetic resonance imaging MRI) system was used to evaluate the response of a human tumour xenograft model to radiation therapy. The apparent diffusion coefficient ADC) and the transverse relaxation time T2) of human glioblastoma multiforme GBM) tumour xenografts in NIH-iii nude mice were measured before, and at multiple points after, treatment of the tumours with 200 kVp x-rays. The response was characterized as a function of a number of variables of interest in the clinical treatment of cancer with external beam radiation therapy. Mean tumour ADC and T2 responses after single fractions of radiation were investigated, with measurements being made until 14 days after treatment.

Single fraction doses ranged from 50 cGy to 800 cGy. Fractionated treatments were used to deliver 800 cGy in two or three fractions with fraction spacings of 24 or 72 hours. The role of hypoxia on ADC and T2 response was investigated by using an externally-applied, suture-based ligature to induce a state of reduced oxygenation in tumours during treatment, after which ADC and T2 were measured using serial MRI. Finally, tumours were dissected in order to provide insight into possible pathophysiological mechanisms explaining the observed responses.

Tissue sections were prepared and reviewed by a pathologist. This work adds to the body of literature describing tumour ADC and T2 response to anticancer therapy, and adds to the understanding of ADC and T2 response to radiation therapy in particular. This works supports that of others suggesting the use of ADC and T2 as potential biomarkers for tumour xenograft model response to treatment.